1
|
Lindsay J, Sharma B, Felt KD, Giobbie-Hurder A, Dryg I, Weirather JL, Altreuter J, Mazor T, Kumari P, Alessi JV, Nirmal AJ, Manos MP, Kumar AR, Lotter W, Cerami E, Johnson BE, Lindeman NI, Sholl LM, Nowak JA, Rodig SJ. Abstract 5706: ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Tumor-infiltrating lymphocyte (TIL) density has been identified as a prognostic and predictive biomarker in select tumors treated with defined therapies. These observations suggest that TILs may be general markers of patient outcomes, but evidence in support of this hypothesis has been limited by small cohorts.
We validated ImmunoPROFILE, a multiplexed immunofluorescence (MIF)-based assay coupled with machine-learning-based image analysis, to identify and quantify tumor cells (cytokeratin, PAX5, PAX8, SOX10), T cells (CD8), T-regulatory cells (FOXP3), exhausted cells (PD-1) and immunosuppressive tumor and immune cells (PD-L1). We applied the MIF panel to specimens from patients collected prospectively over three years and analyzed 2,023 cases across 27 tumor types. The association between biomarkers and overall survival (OS) was investigated using Cox models controlling for patient risk factors such as cancer type, metastatic vs. primary disease, age, and gender. Multivariable biomarker selection was based on likelihood ratios.
The assay was highly robust (success rate 97%), reproducible (inter-scanning and intra-staining density controls within 1 SD, inter-staining PD-L1 scores ≤11% CV), and operator-independent (R2 >0.7 to >0.9 for each biomarker and 95% concordance in PD-L1 score-based interpretation between technicians). From whole slide images, a total of 11,932 individual regions of interest were analyzed across the cohort, resulting in >50 million spatially-resolved single cells which were summarized into cell population densities and PD-L1 scores.
High densities of CD8+ (>64/mm2, p<0.0001), PD-1+ (>50/mm2, p<0.0001), and FOXP3+ (>30/mm2, p<0.0001) T cells were associated with longer overall survival (OS) irrespective of therapy and across all cancer types. PD-L1 metrics were not associated with OS (p=0.43). Compared to patients with low densities of CD8+ and PD-1+ cells, high densities of at least one of these cell types had better OS (Both high, HR: 0.49, 95% CI: 0.41 - 0.59; CD8+ high, HR: 0.63, (0.48 - 0.82); PD-1+ high, HR: 0.71, (0.54 - 0.93)). The results were consistent in the subset of patients (N=1572) who did not receive immunotherapy (IO). In patients who received IO therapy (N=451), only PD-1+ T-cell density associated with OS (HR: 0.48, (0.36 - 0.65)).
To our knowledge, this is the first enterprise-level immune biomarker assay using multiplexed staining, digital imaging, and machine learning to be applied in a prospective manner to clinical specimens at scale. We found that select immune cell densities are prognostic across cancer types and therapies and demonstrated that quantification of multiple cell populations yields better prognostic power than single marker analyses.
Citation Format: James Lindsay, Bijaya Sharma, Kristen D. Felt, Anita Giobbie-Hurder, Ian Dryg, Jason L. Weirather, Jennifer Altreuter, Tali Mazor, Priti Kumari, Joao V. Alessi, Ajit J. Nirmal, Michael P. Manos, Ananth R. Kumar, William Lotter, Ethan Cerami, Burce E. Johnson, Neil I. Lindeman, Lynette M. Sholl, Jonathan A. Nowak, Scott J. Rodig. ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5706.
Collapse
Affiliation(s)
| | - Bijaya Sharma
- 2ImmunoProfile, Brigham and Women’s Hospital, Boston, MA
| | | | | | - Ian Dryg
- 1Dana-Farber Cancer Institute, Boston, MA
| | | | | | - Tali Mazor
- 1Dana-Farber Cancer Institute, Boston, MA
| | | | - Joao V. Alessi
- 3Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - Ajit J. Nirmal
- 4Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | | | | | | | | | - Burce E. Johnson
- 4Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - Neil I. Lindeman
- 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
| | | | | | | |
Collapse
|
2
|
Garrido-Castro AC, Hughes ME, Cherniack A, Barroso-Sousa R, Bychkovsky BL, Di Lascio S, Berger A, Mittendorf EA, Files JL, Guo H, Kumari P, Cerami E, Krop IE, Wagle N, Lindeman NI, MacConaill LE, Dillon DA, Winer EP, Lin NU. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd9-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Discordance in hormone receptor (HR) status between primary (p) tumors and metastatic (m) recurrences has been widely described. Loss of estrogen and progesterone receptor expression occurs in ˜12% of asynchronous recurrences, leading to triple-negative (TN) status in the metastasis. Genomic mechanisms driving HR loss and its prognostic and therapeutic implications have not been fully elucidated.
Methods: Targeted NGS (Oncopanel, OP) at Dana-Farber Cancer Institute using multiplexed copy number variation and mutation (mut) detection across the full coding regions of 300 genes and selected intronic regions of 35 genes was prospectively performed on either archival primary or metastatic samples collected in patients (pts) with metastatic breast cancer (MBC). Receptor status at initial diagnosis and recurrence were reviewed using a 1% cutoff to define HR-positivity and excluding HER2+ cases. Fisher´s exact test was used to compare frequency of alterations. Tumor mut burden (TMB) was computed normalizing the sum of reported exon mut in each pt by the exonic-bait-set size of the panel.
Results: Between 8/2013-9/2016, 929 pts with MBC underwent OP testing. Of 517 pts diagnosed with primary HR+/HER2- breast cancer, at time of recurrence 388 remained HR+/HER2- (pHR+/mHR+), 39 switched to HR-/HER2- (pHR+/mTN, of which 23 (59%) had initial HR expression >10%), 10 switched to HER2+ and 80 had unknown metastatic receptor status. Comparison between primary samples in pHR+/mHR+ (n=245) and pHR+/mTN (n=24) showed that pHR+/mTN was significantly more likely to harbor mut in TP53, STK11 and MSH6, amplifications (amp) in CCNE1 and FGFR2, and less likely to have PIK3CA mut or CCND1 amp. Median TMB in primary pHR+/mHR+ was 6.05 mut/Mb (0-37.5) and 5.68 mut/Mb (1.2-10.9) in pHR+/mTN (p=0.45). Metastatic samples in pHR+/mTN (n=15) were enriched in ARID1A, CRTC2 and CDH1 mut compared to metastases (n=40) in pts who remained TN (pTN/mTN). Deletions in CDKN2A/2B and RB1, and mut in TP53, NOTCH2 and ERCC2 were more prevalent in recurrent tumors of pHR+/mTN than pHR+/mHR+. In metastases, TMB was higher in pHR+/mTN than pTN/mTN or pHR+/mHR+ (10.9 vs. 7.0 vs. 7.3 mut/Mb, respectively; p=0.002). Median OS from initial diagnosis was 9.4 yrs in pHR+/mTN, less than pHR+/mHR+ (15.9 yrs; p=0.009) and greater than pTN/mTN (4.3 yrs; p=0.008). Median OS from MBC diagnosis was 1.8 yrs in pHR+/mTN, less than pHR+/mHR+ (6.4 yrs; p=0.001) but not significantly different than pTN/mTN (1.5 yrs, p=0.3).
pHR+/mHR+ (n=245)pHR+/mTN (n=24)p value NFreq (%)NFreq (%) MutTP536325.72083.3<0.00001PIK3CA9438.4000GATA33514.3000.053STK1152.0312.50.026MSH641.6312.50.017AmpFGFR20028.30.008CCNE10028.30.008CCND14418.0000.018
Conclusion: Targeted NGS shows that alterations in DNA damage and cell-cycle regulation pathways in primary HR+ tumors are associated with HR loss in the metastatic setting. Primary tumors that lose HR appear more similar to basal-like than luminal tumors, despite >10% baseline HR expression in most pts, and once metastatic, survival is comparable to pTN/mTN. Metastases with HR loss have higher TMB than those that remain HR+ or TN throughout the course of the disease. These findings, if confirmed, may influence treatment and pt selection for clinical trials.
Citation Format: Garrido-Castro AC, Hughes ME, Cherniack A, Barroso-Sousa R, Bychkovsky BL, Di Lascio S, Berger A, Mittendorf EA, Files JL, Guo H, Kumari P, Cerami E, Krop IE, Wagle N, Lindeman NI, MacConaill LE, Dillon DA, Winer EP, Lin NU. Genomic alterations associated with loss of HR expression in metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD9-01.
Collapse
Affiliation(s)
- AC Garrido-Castro
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - ME Hughes
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - A Cherniack
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - R Barroso-Sousa
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - BL Bychkovsky
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - S Di Lascio
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - A Berger
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - EA Mittendorf
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - JL Files
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - H Guo
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - P Kumari
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - E Cerami
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - IE Krop
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - N Wagle
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - NI Lindeman
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - LE MacConaill
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - DA Dillon
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - EP Winer
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| | - NU Lin
- Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women´s Hospital; Harvard Medical School, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
3
|
Barroso-Sousa R, Tyekucheva S, Pernas-Simon S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Tolaney SM. Abstract P5-12-02: PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: To date no biomarker has been identified that predicts response to ICI in mTNBC. This study aimed to explore if tumor genomic alterations correlate with efficacy of PD-1/PD-L1 inhibition in patients (pts) with mTNBC. Methods: Demographic, treatment response, and long-term outcome data were collected on patients with mTNBC treated at Dana-Farber Cancer Institute (DFCI) under several clinical trials incorporating PD-1/PD-L1 inhibitors, given as monotherapy or combined with chemotherapy (CT). Pts included in this analysis had available results of targeted exon sequencing performed using Oncopanel, our institutional gene sequencing panel, on archival tumor tissue. TMB was calculated by determining the number of non-synonymous somatic mutations that occur per megabase of exonic sequence data across all genes on the panel. High TMB was defined as 310 mutations/megabase. TMB and gene alterations were correlated with objective response rate (ORR) per RECIST 1.1, progression-free (PFS) and overall survival (OS). Results: A total of 50 pts with mTNBC were included in this analysis. At baseline, the median age was 55.9 years (31.8–75.9), 60% had ECOG 0 and 40% had ECOG 1, 72% had visceral metastasis, and 46% had received 31 prior lines of systemic therapy in the metastatic setting. While 26% of pts received monotherapy [pembrolizumab (n=7, NCT02447003); atezolizumab (n=6; NCT01375842)], 74% received combination with CT [pembrolizumab plus eribulin (n=31; NCT02513472); atezolizumab plus nab-paclitaxel (n=6; NCT01633970)]. PTEN alterations were present in 30% of pts (mutations = 7; one copy number loss = 7; two copy number loss = 1). Median follow-up was 14 months (1–40). Pts with tumors harboring PTEN alterations had lower ORR (7% vs 57%; P<0.001), shorter median PFS (2.3 vs 6.3 months; P=0.027), and shorter median OS (8.1 vs 20.1 months; P=0.012) compared to pts without PTEN alterations. The median TMB was 6.6 mut/Mb (1.2–50.8), and 23% of pts had a high TMB. While high TMB was not associated with higher ORR (P=0.56), it was associated with better median PFS (16.5 vs 2.4 months; P=0.017), and better median OS (not reached vs 13.5 months; P=0.026). Both PTEN status and TMB remained significantly associated with PFS in the multivariable model. Only PTEN status remained significantly associated with OS in the multivariable analysis with the same covariables. Ongoing analysis to better understand if these predictors are specific for predicting benefit to immunotherapy and/or a marker of chemotherapy resistance will be presented at the symposium. Conclusion: PTEN genomic alterations and TMB may impact benefit from PD-1/PD-L1 inhibitors largely administered with chemotherapy in mTNBC. These observations warrant prospective validation and may inform the importance of stratifying pts according to these characteristics in future randomized studies with ICI.
Table 1.Multivariable analysis for PFS Hazard ratioConfidence Intervalp-valueCombination therapy0.420.16 – 1.130.009Visceral metastasis1.310.63 – 2.770.46Previous lines of therapy1.020.09 – 0.700.85ECOG 12.11.06 – 1.280.034PTEN altered3.741.65 – 8.440.002Hypermutated tumors0.850.75 – 0.970.011
Citation Format: Barroso-Sousa R, Tyekucheva S, Pernas-Simon S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Di Lascio S, Umeton R, Files J, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Tolaney SM. PTEN alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-02.
Collapse
Affiliation(s)
- R Barroso-Sousa
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - S Tyekucheva
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - S Pernas-Simon
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - P Exman
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - E Jain
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - AC Garrido-Castro
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - M Hughes
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - B Bychkovsky
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - S Di Lascio
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - R Umeton
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - J Files
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - NI Lindeman
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - LE MacConaill
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - FS Hodi
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - IE Krop
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - D Dillon
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - EP Winer
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - N Wagle
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - NU Lin
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - EA Mittendorf
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| | - SM Tolaney
- Dana-Farber Cancer Institute, Boston, MA; Harvard Medichal School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA; Brigham and Women´s Hospital, Boston, MA; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston
| |
Collapse
|
4
|
Exman P, Garrido-Castro A, Hughes ME, Freedman RA, Ma C, Bose R, Cerami E, Wagle N, Barroso-Sousa R, Fitz CD, Lindeman NI, MacConaill L, Bychkovsky BL, Lloyd MR, Mackichan CR, Kumari P, Tolaney SM, Krop IE, Winer EP, Dillon DA, Lin NU. Abstract P4-04-02: Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Tailored treatment trials with biomarker-driven hypotheses are becoming an important strategy in drug development. Umbrella, basket and enrichment trials with eligibility predicated upon results of tumor sequencing are increasingly common. Several institutional and commercial genomic assays have been developed. However, the value of broad-based testing in recruiting patients (pts) to molecular-based clinical trials designed for small subgroups has not been fully evaluated and has been challenging to assess in a real-world setting. We evaluated the likelihood of trial enrollment based upon an institute-wide genomic test.
Methods
Since 2013, all pts with metastatic breast cancer (MBC) seen at least once at Dana-Farber Cancer Institute have been offered the option of tumor sequencing using multiplexed copy number variation (CNV) and mts detection across the full coding regions of a total of 447 cancer genes and 191 regions across 60 genes for rearrangement detection (Oncopanel; OP). For our primary analysis, we selected the ongoing multi-center phase II trial (NCT01670877) activated at our site on Sep 30, 2013, evaluating neratinib in ERBB-2 mutated pts, as the study provided a clear delineation of eligible mts, and timing of slot availability was retrievable retrospectively over an extended time frame. Our primary aim was to describe the proportion of pts with a qualifying ERBB-2 mt detected by OP who enrolled on the selected trial. Secondary objectives included median time from OP result to trial registration and description of ERBB-2 mts spectrum within each subtype. Associations were calculated by Fisher's test.
Results
We identified a total of 1,046 pts with HER-2 negative MBC and who had OP results between Sep 1, 2013 and Jun 1, 2017. A total of 43 pts (4.1%) were found to have ERBB-2 mts. Of these, 20 (1.9%) had activating eligible mts. The proportion of these pts who enrolled in the trial was 30% (6/20). Of the remaining 14 pts, 5 screen-failed and 2 were enrolled with known ERBB-2 mt through other testing modalities. Seven of 20 (35%) molecularly eligible pts were not approached (3 pts lost to follow-up, 3 enrolled in other clinical trials and 1 pt chose standard treatment). The median time from OP result to trial enrollment was 85 days (34-554). A significantly higher frequency of ERBB2 activating mts was found in ER+ compared to ER- primary tumors (2.5% vs. 0.3%, p =0.036), and in lobular tumors compared with ductal (5.5% vs. 1.25%, p=0.003). Frequency of eligible mts in primary tumors were similar to metastatic site (1.9% and 1.8%, respectively p=1.0)
Discussion
In this cohort, activating ERBB-2 mts were present in 20 of 1046 (1.9%) pts tested. Although over half of pts with eligible mts on OP testing were approached for NCT01670877, only 0.5% of the total tested population were enrolled (6/1046). Our data illustrate the substantial challenges in screening and enrolling to trials of rare subsets, even within a large academic institution, and point to the need for creative and novel approaches to leverage pts and community- and academic-based providers to more effectively support the success of such studies.
Citation Format: Exman P, Garrido-Castro A, Hughes ME, Freedman RA, Ma C, Bose R, Cerami E, Wagle N, Barroso-Sousa R, Fitz CD, Lindeman NI, MacConaill L, Bychkovsky BL, Lloyd MR, Mackichan CR, Kumari P, Tolaney SM, Krop IE, Winer EP, Dillon DA, Lin NU. Identifying ERBB-2 activating mutations (mts) in HER2 negative tumors for clinical trials – Impact of institute-wide genomic testing and trial matching on trial enrollment in clinical practice [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-04-02.
Collapse
Affiliation(s)
- P Exman
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - A Garrido-Castro
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - ME Hughes
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - RA Freedman
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - C Ma
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - R Bose
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - E Cerami
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - N Wagle
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - R Barroso-Sousa
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - CD Fitz
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - NI Lindeman
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - L MacConaill
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - BL Bychkovsky
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - MR Lloyd
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - CR Mackichan
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - P Kumari
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - SM Tolaney
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - IE Krop
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - EP Winer
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - DA Dillon
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| | - NU Lin
- Dana Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St Louis, St. Louis, MO; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|